Company news

Prothena Corporation plc news in 2024

Prothena Corporation plc's news releases, calls and decks from 2024, newest first.

View company

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

November 11, 2024

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

August 7, 2024

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 27, 2024

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024

Prothena to Report First Quarter 2024 Financial Results on May 8

April 30, 2024

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

April 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer Position

March 3, 2024

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

February 20, 2024

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

February 14, 2024

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

February 7, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

January 7, 2024

Calls in 2024

Decks in 2024